Targeting a specific cell death pathway in a type of aggressive thyroid cancer.
Targeting Ferroptosis in BRAF (V600E) Mutant Anaplastic Thyroid Cancer
This study is looking at a new treatment for anaplastic thyroid cancer that has a specific mutation, aiming to see if combining two types of drugs can help make the cancer cells die more effectively, which could lead to better results for patients facing this tough condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10877833 on NIH RePORTER |
What this research studies
This research focuses on anaplastic thyroid cancer (ATC) that often has a mutation known as BRAFV600E, which makes it resistant to standard treatments. The study aims to explore a new approach that combines BRAF inhibitors with agents that induce ferroptosis, a unique form of cell death that is particularly effective in these cancer cells. By understanding how these treatments work together, the researchers hope to improve outcomes for patients with this challenging cancer. The research involves laboratory experiments to test the effectiveness and safety of this combination therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with anaplastic thyroid cancer that has the BRAFV600E mutation.
Not a fit: Patients with anaplastic thyroid cancer who do not have the BRAFV600E mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with BRAFV600E-mutant anaplastic thyroid cancer.
How similar studies have performed: Other research has shown promise in targeting ferroptosis in cancer treatment, suggesting that this approach could be a viable option for improving patient outcomes.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Kebebew, Electron — Stanford University
- Study coordinator: Kebebew, Electron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.